BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 9427741)

  • 1. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus.
    Müller S; Matunis MJ; Dejean A
    EMBO J; 1998 Jan; 17(1):61-70. PubMed ID: 9427741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
    Sternsdorf T; Puccetti E; Jensen K; Hoelzer D; Will H; Ottmann OG; Ruthardt M
    Mol Cell Biol; 1999 Jul; 19(7):5170-8. PubMed ID: 10373566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation.
    Lallemand-Breitenbach V; Zhu J; Puvion F; Koken M; Honoré N; Doubeikovsky A; Duprez E; Pandolfi PP; Puvion E; Freemont P; de Thé H
    J Exp Med; 2001 Jun; 193(12):1361-71. PubMed ID: 11413191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3.
    Fu C; Ahmed K; Ding H; Ding X; Lan J; Yang Z; Miao Y; Zhu Y; Shi Y; Zhu J; Huang H; Yao X
    Oncogene; 2005 Aug; 24(35):5401-13. PubMed ID: 15940266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
    Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z
    Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.
    Percherancier Y; Germain-Desprez D; Galisson F; Mascle XH; Dianoux L; Estephan P; Chelbi-Alix MK; Aubry M
    J Biol Chem; 2009 Jun; 284(24):16595-16608. PubMed ID: 19380586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML.
    Kunapuli P; Kasyapa CS; Chin SF; Caldas C; Cowell JK
    Exp Cell Res; 2006 Nov; 312(19):3739-51. PubMed ID: 17027752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SUMO deconjugation is required for arsenic-triggered ubiquitylation of PML.
    Fasci D; Anania VG; Lill JR; Salvesen GS
    Sci Signal; 2015 Jun; 8(380):ra56. PubMed ID: 26060329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.
    Wang ZG; Rivi R; Delva L; König A; Scheinberg DA; Gambacorti-Passerini C; Gabrilove JL; Warrell RP; Pandolfi PP
    Blood; 1998 Sep; 92(5):1497-504. PubMed ID: 9716575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway.
    Lallemand-Breitenbach V; Jeanne M; Benhenda S; Nasr R; Lei M; Peres L; Zhou J; Zhu J; Raught B; de Thé H
    Nat Cell Biol; 2008 May; 10(5):547-55. PubMed ID: 18408733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PML and PML/RARalpha domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic.
    Andre C; Guillemin MC; Zhu J; Koken MH; Quignon F; Herve L; Chelbi-Alix MK; Dhumeaux D; Wang ZY; Degos L; Chen Z; de The H
    Exp Cell Res; 1996 Dec; 229(2):253-60. PubMed ID: 8986606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
    Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
    Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells.
    Müller S; Miller WH; Dejean A
    Blood; 1998 Dec; 92(11):4308-16. PubMed ID: 9834237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation.
    Duprez E; Saurin AJ; Desterro JM; Lallemand-Breitenbach V; Howe K; Boddy MN; Solomon E; de Thé H; Hay RT; Freemont PS
    J Cell Sci; 1999 Feb; 112 ( Pt 3)():381-93. PubMed ID: 9885291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies.
    Adamson AL; Kenney S
    J Virol; 2001 Mar; 75(5):2388-99. PubMed ID: 11160742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of Pax3 transcriptional activity by SUMO-1-modified PML.
    Lehembre F; Müller S; Pandolfi PP; Dejean A
    Oncogene; 2001 Jan; 20(1):1-9. PubMed ID: 11244500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors.
    Lin DY; Huang YS; Jeng JC; Kuo HY; Chang CC; Chao TT; Ho CC; Chen YC; Lin TP; Fang HI; Hung CC; Suen CS; Hwang MJ; Chang KS; Maul GG; Shih HM
    Mol Cell; 2006 Nov; 24(3):341-54. PubMed ID: 17081986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The promyelocytic leukemia protein stimulates SUMO conjugation in yeast.
    Quimby BB; Yong-Gonzalez V; Anan T; Strunnikov AV; Dasso M
    Oncogene; 2006 May; 25(21):2999-3005. PubMed ID: 16501610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic trioxide stimulates SUMO-2/3 modification leading to RNF4-dependent proteolytic targeting of PML.
    Weisshaar SR; Keusekotten K; Krause A; Horst C; Springer HM; Göttsche K; Dohmen RJ; Praefcke GJ
    FEBS Lett; 2008 Sep; 582(21-22):3174-8. PubMed ID: 18708055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of SUMO-1-modified PML in nuclear body formation.
    Zhong S; Müller S; Ronchetti S; Freemont PS; Dejean A; Pandolfi PP
    Blood; 2000 May; 95(9):2748-52. PubMed ID: 10779416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.